Henry Schein Approves Key Proposals at Annual Meeting

Henry Schein ( (HSIC) ) just unveiled an announcement.

On May 22, 2025, Henry Schein, Inc. held its 2025 Annual Meeting of Stockholders where key proposals were approved, including the election of twelve directors for terms expiring in 2026, and the election of Max Lin and William K. ‘Dan’ Daniel as directors. The meeting also saw the approval of the 2024 compensation for Named Executive Officers and the ratification of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 27, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.

The most recent analyst rating on (HSIC) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.

Spark’s Take on HSIC Stock

According to Spark, TipRanks’ AI Analyst, HSIC is a Outperform.

Henry Schein demonstrates solid financial performance with effective cost management and strategic growth initiatives. Technical indicators suggest potential short-term caution, while valuation remains fair. Recent corporate events reinforce strategic positioning, supporting a stable outlook with growth potential.

To see Spark’s full report on HSIC stock, click here.

More about Henry Schein

Henry Schein, Inc. operates in the healthcare industry, providing a wide range of products and services to dental and medical practitioners. The company focuses on delivering healthcare solutions and is a leading provider in the healthcare distribution market.

Average Trading Volume: 1,873,381

Technical Sentiment Signal: Buy

Current Market Cap: $8.68B

For a thorough assessment of HSIC stock, go to TipRanks’ Stock Analysis page.